Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer

Dr. Wainberg, Co-Director, UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, considers the Phase 2 REACHIN study investigating regorafenib in locally advanced biliary tract cancer

• Categoria